[go: up one dir, main page]

PE20091713A1 - Inhibicion del receptor para la proteina estimulante del macrofago (ron), composiciones y metodos - Google Patents

Inhibicion del receptor para la proteina estimulante del macrofago (ron), composiciones y metodos

Info

Publication number
PE20091713A1
PE20091713A1 PE2008001959A PE2008001959A PE20091713A1 PE 20091713 A1 PE20091713 A1 PE 20091713A1 PE 2008001959 A PE2008001959 A PE 2008001959A PE 2008001959 A PE2008001959 A PE 2008001959A PE 20091713 A1 PE20091713 A1 PE 20091713A1
Authority
PE
Peru
Prior art keywords
seq
macrophagus
ron
receptor
inhibition
Prior art date
Application number
PE2008001959A
Other languages
English (en)
Inventor
Daniel Pereira
Jennifer O'toole
Original Assignee
Imclone Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40364492&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20091713(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Imclone Llc filed Critical Imclone Llc
Publication of PE20091713A1 publication Critical patent/PE20091713A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

REFERIDA A UN ANTICUERPO O FRAGMENTO DE ANTICUERPO QUE SE UNE ESPECIFICAMENTE A UNA PROTEINA RON (PROTEINA ESTIMULANTE DEL MACROFAGO) QUE COMPRENDE UNA CDR SELECCIONADA DE SEQ ID NO: 17; SEQ ID NO 19; SEQ ID NO 21; SEQ ID NO 23, SEQ ID NO 25, SEQ ID NO 27, SEQ ID NO 29, SEQ ID NO 31, SEQ ID NO 33, SEQ ID NO 35, SEQ ID NO 37 Y SEQ ID NO 39. TAMBIEN ESTA REFERIDA A UN VECTOR RECOMBINANTE, UNA CELULA HUESPED Y A UNA COMPOSICION FARMACEUTICA. DICHOS ANTICUERPOS SON UTILES EN EL TRATAMIENTO DEL CANCER
PE2008001959A 2007-11-21 2008-11-24 Inhibicion del receptor para la proteina estimulante del macrofago (ron), composiciones y metodos PE20091713A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US98955807P 2007-11-21 2007-11-21

Publications (1)

Publication Number Publication Date
PE20091713A1 true PE20091713A1 (es) 2009-11-13

Family

ID=40364492

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008001959A PE20091713A1 (es) 2007-11-21 2008-11-24 Inhibicion del receptor para la proteina estimulante del macrofago (ron), composiciones y metodos

Country Status (20)

Country Link
US (2) US7947811B2 (es)
EP (1) EP2222703A2 (es)
JP (1) JP5324593B2 (es)
KR (1) KR101227338B1 (es)
CN (1) CN101868478B (es)
AR (1) AR069393A1 (es)
AU (1) AU2008330089B2 (es)
BR (1) BRPI0820218A2 (es)
CA (1) CA2706583A1 (es)
CL (1) CL2008003449A1 (es)
EA (1) EA018717B1 (es)
IL (1) IL204743A (es)
MX (1) MX2010005651A (es)
NZ (1) NZ584271A (es)
PA (1) PA8804901A1 (es)
PE (1) PE20091713A1 (es)
TW (1) TWI417106B (es)
UA (1) UA99633C2 (es)
UY (1) UY31478A1 (es)
WO (1) WO2009070294A2 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602006010874D1 (de) 2005-07-22 2010-01-14 Five Prime Therapeutics Inc Zusammensetzungen und verfahren zur behandlung von krankheiten mit fgfr-fusionsproteinen
CN101977937A (zh) * 2008-01-22 2011-02-16 拜奥根Idec马萨诸塞公司 Ron抗体及其用途
JP2011511005A (ja) 2008-02-04 2011-04-07 オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド ２−アミノピリジン系キナーゼ阻害薬
AR070317A1 (es) 2008-02-06 2010-03-31 Osi Pharm Inc Furo (3,2-c) piridina y tieno (3,2-c) piridinas
TWI480050B (zh) * 2009-02-10 2015-04-11 Daiichi Sankyo Co Ltd 抗－ｍｓｔ１ｒ抗體及其用途
RS55229B1 (sr) * 2009-12-29 2017-02-28 Emergent Product Dev Seattle Heterodimerni vezujući proteini i njihove upotrebe
US8603478B2 (en) 2010-07-06 2013-12-10 Aveo Pharmaceuticals, Inc. Anti-RON antibodies
US8481038B2 (en) 2010-11-15 2013-07-09 Five Prime Therapeutics, Inc. Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins
US8951972B2 (en) * 2010-12-09 2015-02-10 Five Prime Therapeutics, Inc. FGFR1 extracellular domain combination therapies for lung cancer
EP2699256B1 (en) 2011-04-21 2017-09-27 The Regents of the University of Colorado, a body corporate Compositions and methods for the treatment of neuromyelitis optica
CA2843158A1 (en) 2011-08-26 2013-03-07 Merrimack Pharmaceuticals, Inc. Tandem fc bispecific antibodies
HK1202240A1 (en) 2011-11-14 2015-09-25 戊瑞治疗有限公司 Methods of treating cancer
JP2016507480A (ja) * 2012-11-30 2016-03-10 ジェネンテック， インコーポレイテッド Ｒｏｎ組成物及びそれらの使用方法
RU2015140921A (ru) * 2013-02-26 2017-04-03 Роше Гликарт Аг Антитела к mcsp
TW201444872A (zh) 2013-03-06 2014-12-01 Merrimack Pharmaceuticals Inc 抗Ｃ－ＭＥＴ串聯Ｆｃ雙特異性抗體
JP6779858B2 (ja) * 2014-07-29 2020-11-04 ウェルマーカー バイオ カンパニー リミテッド Ｅｇｆｒ−標的製剤に対する感受性予測用の新規なバイオマーカー及びその用途
CN107406492B (zh) * 2014-09-03 2021-12-24 井标记生物 用于预测对蛋白激酶抑制剂的敏感性的生物标记物及其用途
JP2020500834A (ja) * 2016-08-26 2020-01-16 エージェンシー フォー サイエンス，テクノロジー アンド リサーチ マクロファージ刺激タンパク質受容体（又はＲＯＮ（Ｒｅｃｅｐｔｅｕｒ ｄ′Ｏｒｉｇｉｎｅ Ｎａｎｔａｉｓ））抗体及びその使用
CN110799211B (zh) 2016-09-08 2024-11-22 美国德州精准药靶有限公司 特异性识别丛蛋白-信号素-整合素结构域的抗ron单克隆抗体的药物呈递作用及其在肿瘤治疗中的应用
WO2021066751A1 (en) * 2019-10-02 2021-04-08 Aslan Pharmaceuticals Pte. Ltd. Antigen specific binding domains and antibody molecules
CA3192706A1 (en) * 2020-09-15 2022-03-24 Gregory SEMPOWSKI Coronavirus antibodies and uses thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
AU612370B2 (en) 1987-05-21 1991-07-11 Micromet Ag Targeted multifunctional proteins
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
EP0536350B1 (en) 1991-02-22 2002-08-07 American Cyanamid Company Identification of a novel human receptor tyrosine kinase gene
ATE463573T1 (de) 1991-12-02 2010-04-15 Medimmune Ltd Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
US5861301A (en) 1992-02-20 1999-01-19 American Cayanamid Company Recombinant kinase insert domain containing receptor and gene encoding same
EP3103799B1 (en) 1995-03-30 2018-06-06 OSI Pharmaceuticals, LLC Quinazoline derivatives
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US20020103345A1 (en) 2000-05-24 2002-08-01 Zhenping Zhu Bispecific immunoglobulin-like antigen binding proteins and method of production
JP2004527456A (ja) 2000-08-09 2004-09-09 イムクローン システムズ インコーポレイティド Ｅｇｆ受容体拮抗剤による過増殖性の疾患の治療
SE518548C2 (sv) 2001-04-11 2002-10-22 Sca Hygiene Prod Ab Absorberande alster med förbättrad diskretion
US7235523B2 (en) 2001-04-13 2007-06-26 Children's Hospital Medical Center Methods for the treatment of hepatic disorders
JP2005500034A (ja) 2001-06-20 2005-01-06 プロション バイオテク リミテッド 受容体型タンパク質チロシンキナーゼ活性化を遮断する抗体、そのスクリーニング方法、及びその使用
WO2003075840A2 (en) 2002-03-04 2003-09-18 Imclone Systems Incorporated Human antibodies specific to kdr and uses thereof
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
US20040185506A1 (en) 2003-03-21 2004-09-23 Heavner George A. Epitope mapping using nuclear magnetic resonance
EP2365001A3 (en) 2003-05-01 2012-03-28 Imclone LLC Fully human antibodies directed against the human insulin-like growth factor-1 receptor
JP2008508858A (ja) * 2004-05-13 2008-03-27 イムクローン システムズ インコーポレイティド マクロファージ−刺激タンパク質受容体（ｒｏｎ）の阻害

Also Published As

Publication number Publication date
UY31478A1 (es) 2009-07-17
JP2011504176A (ja) 2011-02-03
TWI417106B (zh) 2013-12-01
TW200936161A (en) 2009-09-01
CN101868478A (zh) 2010-10-20
IL204743A (en) 2013-10-31
PA8804901A1 (es) 2009-06-23
EA201070636A1 (ru) 2010-10-29
MX2010005651A (es) 2010-06-11
US8133489B2 (en) 2012-03-13
NZ584271A (en) 2012-05-25
AU2008330089A1 (en) 2009-06-04
AU2008330089B2 (en) 2013-09-05
CN101868478B (zh) 2013-11-13
US20090136510A1 (en) 2009-05-28
IL204743A0 (en) 2010-11-30
WO2009070294A3 (en) 2009-08-20
AR069393A1 (es) 2010-01-20
UA99633C2 (ru) 2012-09-10
JP5324593B2 (ja) 2013-10-23
CL2008003449A1 (es) 2010-02-19
CA2706583A1 (en) 2009-06-04
EP2222703A2 (en) 2010-09-01
BRPI0820218A2 (pt) 2015-06-23
KR101227338B1 (ko) 2013-01-28
US7947811B2 (en) 2011-05-24
EA018717B1 (ru) 2013-10-30
US20110135631A1 (en) 2011-06-09
KR20100074293A (ko) 2010-07-01
WO2009070294A2 (en) 2009-06-04

Similar Documents

Publication Publication Date Title
PE20091713A1 (es) Inhibicion del receptor para la proteina estimulante del macrofago (ron), composiciones y metodos
PE20191463A1 (es) Anticuerpos biespecificos de union especifica pd1 y lag3
PE20120431A1 (es) Anticuerpo antagonista para el tratamiento del cancer
AR060017A1 (es) Composiciones y metodos de uso para anticuerpos de dickkopf -1
PE20110225A1 (es) Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c5
PE20091196A1 (es) Anticuerpos contra el vegf completamente humano, composiciones y metodos
CY1115572T1 (el) Αντι cxcr4 αντισωματα και χρηση αυτων για τη θεραπεια καρκινου
PE20091163A1 (es) Anticuerpos para gdf8
ATE502052T1 (de) Monoklonale antikörper gegen den humanen anti- müllerian-hormonrezeptor vom typ ii (amhr-ii)
EA201100546A1 (ru) Полипептиды, вариабельные домены антител и антагонисты
MX2009002711A (es) Anticuerpos anti-receptor de folato alfa humanos y fragmentos de anticuerpo para la radioinmunoterapia de carcinoma de ovario.
PH12013502043A1 (en) T cell receptor-like antibodies specific for a wt1 peptide presented by hla-a2
PE20121129A1 (es) Anticuerpos humanos de alta afinidad para la angiopoyetina-2 humana
PE20130207A1 (es) Anticuerpos antagonistas de lrp6 (proteina relacionada con lipoproteinas de baja densidad 6) y composiciones
EA201170590A1 (ru) Ингибиторы рецептора фактора роста фибробластов-3 (fgfr-3) и способы лечения
CL2012000914A1 (es) Anticuerpos monoclonales que se unen especificamente a la region c-terminal de progastrina. uso para la preparacion de un medicamento util en el tratamiento de cancer colorectal.
EA201992526A1 (ru) Стабильные составы анти-ctla4 антител, отдельно и в комбинации с антителами против рецептора 1 программируемой смерти (pd-1), и способы их применения
CA2793647A1 (en) Prophylaxis of colorectal and gastrointestinal cancer
UA95068C2 (uk) Антиген-зв'язуюча молекула, яка зв'язує еgfr, вектор, що її кодує, та їх застосування
PE20091193A1 (es) Proteinas humanas de union a antigenos del gm-csf
UA106194C2 (ru) Диагностика и лечение рака с применением антитела к ereg
EA201201533A1 (ru) Prlr-специфическое антитело и его применения
PE20180502A1 (es) Composiciones anti-cgrp y uso de las mismas
BRPI0613382A8 (pt) anticorpos isolados, anticorpo monoclonal, célula de hibridoma, método de identificação, método de inibição do crescimento de uma célula, método de tratamento terapêutico, método de determinação da presença de uma proteína, métodos de diagnósticos da presença de tumor
PE20120902A1 (es) Anticuerpos anti-egfl7 humanizados

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed